Novo Nordisk cuts some US supply of obesity drug Wegovy to cope with demand https://ift.tt/O95rNv3

Shares in Novo Nordisk traded down 4.7 per cent at 0731 GMT, putting a small dent in a rise of more than 140 per cent since the firm launched Wegovy in the U.S. in June 2021. The company's stock is the best performing in Europe.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/MGFnub3